1 Eligibility criteria included (
1) subjects exposed to trauma
2 Eligibility criteria included:
1) residence in defined zip co
3 Eligibility criteria included a body mass index (BMI; in kg/m
4 Eligibility criteria included a diagnosis of RS or secondary
5 Eligibility criteria included a distance control score of 2 o
6 Eligibility criteria included a prostate-specific antigen (PS
7 Eligibility criteria included a recently diagnosed adenoma an
8 Other
eligibility criteria included adequate organ function and goo
9 Eligibility criteria included advanced CRC that had progresse
10 Patient
eligibility criteria included age 18 years or older, Eastern
11 Eligibility criteria included age 2 to 17 years, AD diagnosis
12 Eligibility criteria included age 6 years or older, infection
13 Eligibility criteria included age of 6 to 18 years, a forced
14 Eligibility criteria included age older than 18 years and no
15 Eligibility criteria included age older than 18 years, receiv
16 Eligibility criteria included age>6.0 yr, FEV1>or=40% predict
17 Eligibility criteria included all studies reporting on the pr
18 Eligibility criteria included an age of 18 years or older, sm
19 Eligibility criteria included an age of 2-25 y, progressive d
20 Eligibility criteria included any published English-language
21 Eligibility criteria included assessment of macronutrient qua
22 Eligibility criteria included at least one radiologically con
23 Eligibility criteria included bidimensionally measurable dise
24 Eligibility criteria included confirmation of diagnosis, resi
25 Additional
eligibility criteria included disease duration of 2-10 years
26 Eligibility criteria included Eastern Cooperative Oncology Gr
27 Key
eligibility criteria included evaluable disease, Eastern Coop
28 Principal
eligibility criteria included exacerbation in corneal stainin
29 Patient
eligibility criteria included having been treated with three
30 Eligibility criteria included histologic diagnosis of Interna
31 The
eligibility criteria included histologically or cytologically
32 Common
eligibility criteria included &
lt;25% bone marrow involvement by
33 Key
eligibility criteria included measurable disease, failure of
34 Eligibility criteria included no history of genital warts or
35 Key
eligibility criteria included no history of virological failu
36 Key
eligibility criteria included no history of virological failu
37 Eligibility criteria included observational studies reporting
38 Eligibility criteria included patients who received a diagnos
39 Eligibility criteria included patients with one of the cancer
40 Eligibility criteria included patients with relapsed/refracto
41 Patients and Materials Study
eligibility criteria included patients with stage II to III N
42 Eligibility criteria included previous normal vision for >/=1
43 Eligibility criteria included regularly scheduled blood trans
44 Eligibility criteria included resectable stage I to III cance
45 Eligibility criteria included screening HIV RNA concentration
46 Eligibility criteria included stage IV or locally advanced st
47 Eligibility criteria included studies evaluating graft thickn
48 Eligibility criteria included T3-T4N0M0 or T1-T4N1M0 esophage
49 Eligibility criteria included the occurrence of a subarachnoi
50 Eligibility criteria included WHO performance status 0 or 1,